Phase I Study on the Safety, Tolerability, and Pharmacodynamic Effects of ASP4345 for the
Treatment of Cognitive Impairment in Patients With Schizophrenia
Presented at the 2019 Congress of the Schizophrenia International Research Society’s (SIRS)
Cognitive impairment associated with schizophrenia (CIAS) includes significant deficits in attention/vigilance, speed of processing, working memory, verbal learning, visual learning, reasoning, and problem solving.
This impairment is present in patients with schizophrenia who are on antipsychotics or naive to treatment1 and currently, no pharmacotherapy has demonstrated efficacy in improving CIAS in clinical trials.